Johnson & Johnson receives first EU approval for third generation DES (drug-eluting stent):
This article was originally published in Clinica
Executive Summary
Johnson & Johnson (J&J) has received the first CE-marking for a third generation drug-eluting stent (DES), for its Cypher Select Plus product to treat coronary artery blockages. The device features a hydrophilic coating technology, called cyph2onic, that makes the device more lubricious, allowing it to be more easily delivered into the arteries. The company expects a full market launch for the product in Europe by the end of 2006. The Cypher Select Plus DES was developed by Cordis, a subsidiary of J&J.